Figure S2
Venn diagram of core regulations in different TNBC cohorts and their overlapping regulations. Venn diagram shows the overlap core regulations in TCGA_Array, GEO and TCGA_Seq cohorts.
Figure S3
Cross-talk effect. Core regulations identified by DERA were mapped back to the pathways from Wikipathways database. The edge labels indicate which pathways the regulation comes from in Wikipahtways database. WP289="Myometrial Relaxation and Contraction Pathways", WP408="Oxidative Stress"; WP560="TGF Beta Signaling Pathway"; WP2355="Corticotropin-releasing hormone". Hierarchical clustering of breast cancer in GEO (upper panel) and TCGA_seq (lower panel) cohorts. Heatmap shows the gene expression intensities (log2) of 119 differentially expressed genes. The heatmap was scaled by row. In the heatmap plot, we used euclidean distance measurement and ward.D agglomeration method in R.
Figure S5
Boxplot of log2 expression values of CCNE1 and SKP2 in the different breast cancer groups in TCGA_Seq and GEO datasets. Grouping was based on immunohistochemistry (IHC) staining. Two sided t-test was used and significance was noted by *(p-value < 5.0×10 −3 **(p-value < 5.0×10 −6 ) and *** (p-value < 5.0×10 −10 ).
Figure S6
Core set of regulations and genes for HGS-OvCa. Red and green represent over-expression and under-expression, respectively.
Figure S7
Venn diagram of core regulations in HGS-OvCa discovery and validation sets, and their overlapping regulations. The threshold to define core regulations was 0.4.
Figure S8
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